Results 51 to 60 of about 41,944 (264)

Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma

EJNMMI Research, 2022
Purpose Radiopharmaceuticals targeting poly(ADP-ribose) polymerase (PARP) have emerged as promising agents for cancer diagnosis and therapy. PARP enzymes are expressed in both cancerous and normal tissue.
Chung Ying Chan, Samantha L. Hopkins, Florian Guibbal, Anna Pacelli, Julia Baguña Torres, Michael Mosley, Doreen Lau, Patrick Isenegger, Zijun Chen, Thomas C. Wilson, Gemma Dias, Rebekka Hueting, Véronique Gouverneur, Bart Cornelissen   +13 more
doaj   +1 more source

TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy [PDF]

, 2013
Base damage and topoisomerase I (Top1)-linked DNA breaks are abundant forms of endogenous DNA breakage, contributing to hereditary ataxia and underlying the cytotoxicity of a wide range of anti-cancer agents.
Alagoz, Boyd, Breslin, Caldecott, Chen, Chiang, Ciccia, Dalhus, Das, Demple, Dungey, El-Khamisy, Fu, Godon, Hecht, Hegde, Hudson, Interthal, Interthal, Kato, Katyal, Kummar, Lebedeva, Lindahl, Lindahl, Liu, Loeb, Luo, Madhusudan, Meisenberg, Meryem Alagoz, Mohammed, Morland, Murai, Murai, Nilsen, Owen S. Wells, Pommier, Pourquier, Povirk, Ray Chaudhuri, Rydberg, Sherif F. El-Khamisy, Strom, Sultana, Takashima, Wilson, Xanthoudakis, Yang, Zeng, Zhou   +50 more
core   +1 more source

Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: Clinical and molecular characterization [PDF]

, 2017
Purpose: Maintenance therapy with olaparib has improved progression-free survival in women with high-grade serous ovarian cancer (HGSOC), particularly those harboring BRCA1/2 mutations.
Barrett, J. Carl, Bowtell, David D.l., Burnier, Julia V, Dougherty, Brian A, Gilks, Blake, Gourley, Charlie, Ho, Tony W, Hodgson, Darren, Karakasis, Katherine, Kaye, Stanley B., Kohn, Elise C, Lai, Zhongwu, Lanchbury, Jerry S, Ledermann, Jonathan, Lheureux, Stephanie, Matulonis, Ursula A, O'connor, Mark J, Oza, Amit M, Panzarella, Tony, Robertson, Jane D, Runswick, Sarah, Scott, Clare L, Timms, Kirsten M   +22 more
core   +2 more sources

Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Journal for ImmunoTherapy of Cancer, 2018
Background Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a benefit of combining olaparib with
Kathleen E. Fenerty, Michelle Padget, Benjamin Wolfson, Sofia R. Gameiro, Zhen Su, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, James W. Hodge   +8 more
doaj   +1 more source

IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer

iScience
Summary: Olaparib is a pioneering PARP inhibitor (PARPi) approved for treating castration-resistant prostate cancer (CRPC) tumors harboring DNA repair defects, but clinical resistance has been documented.
Amy R. Leslie, Shu Ning, Cameron M. Armstrong, Leandro S. D’Abronzo, Masuda Sharifi, Zachary A. Schaaf, Wei Lou, Chengfei Liu, Christopher P. Evans, Alan P. Lombard, Allen C. Gao   +10 more
doaj   +1 more source

The combination of olaparib and camptothecin for effective radiosensitization

Radiation Oncology, 2012
Background Poly (ADP-ribose) polymerase-1 (PARP-1) is a key enzyme involved in the repair of radiation-induced single-strand DNA breaks. PARP inhibitors such as olaparib (KU-0059436, AZD-2281) enhance tumor sensitivity to radiation and to topoisomerase I
Miura Katsutoshi, Sakata Koh-ichi, Someya Masanori, Matsumoto Yoshihisa, Matsumoto Hideki, Takahashi Akihisa, Hareyama Masato   +6 more
doaj   +1 more source

Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis

BMC Cancer, 2023
Objective To analyze the incidence and risk of hypertension associated with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in cancer patients and provide reference for clinicians.
Xiu Chen, Qinglian Wen, Liqiu Kou, Xiaolu Xie, Jun Li, Yaling Li   +5 more
doaj   +1 more source

Hypersensitivity of BRCA1 heterozygote lymphoblastoid cells to gamma radiation and PARP inhibitors [PDF]

, 2013
This article is made available through the Brunel Open Access Publishing Fund. Copyright @ 2013 Bourton EC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use ...
Bourton, EC, Foster, HA, Harvey, AJ, Parris, C, Plowman, PN   +4 more
core   +2 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial

Nature Communications
SOLACE2 (ACTRN12618000686202) investigates whether 12-weeks of olaparib, or cyclophosphamide-olaparib priming, improves subsequent durvalumab-olaparib progression-free survival (PFS), and is superior to olaparib monotherapy without any priming, in ...
Chee Khoon Lee, Apriliana E. R. Kartikasari, Nirashaa T. Bound, Katherine E. Francis, Kristy Shield-Artin, Justin Bedo, Ksenija Nesic, Katrina Diamante, Rachel L. O’Connell, Mutsa Madondo, Momodou Cox, Claire Davies, Cyril Deceneux, Georgia Goodchild, Andrew Jarratt, Emily Cassar, Hina Amer, U. G. Imalki U. Kariyawasam, Yeh Chen Lee, Janine Lombard, Sally Baron-Hay, Yoland Antill, Catherine Shannon, Sudarshan Selva-Nayagam, Philip Beale, Danka Zebic, Sandy Simon, Anneliese Linaker, Michael A. Quinn, Anthony T. Papenfuss, Matthew J. Wakefield, Cassandra J. Vandenberg, Michael Friedlander, Clare L. Scott, Magdalena Plebanski   +34 more
doaj   +1 more source